Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Oncolytics Biotech ( (ONCY) ) just unveiled an announcement.
On April 27, 2026, Oncolytics Biotech announced it had reached alignment with the U.S. Food and Drug Administration on the design of a pivotal randomized controlled study of pelareorep in unresectable metastatic squamous cell carcinoma of the anal canal. The trial will target post-standard-of-care patients who currently have no FDA-approved therapies, aiming to support both accelerated and full approval within a single study and leveraging prior data showing improved durability of response and survival versus the existing standard of care.
The company plans to incorporate FDA feedback into a final protocol for this pivotal anal cancer study, positioning pelareorep as a potential new option in a setting of significant unmet medical need. The move underscores Oncolytics’ broader strategy to establish a registrational pathway for pelareorep across multiple gastrointestinal cancers, which could enhance its standing in immuno-oncology and potentially benefit patients, clinicians, and investors if future trial outcomes are favorable.
The most recent analyst rating on (ONCY) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Oncolytics Biotech stock, see the ONCY Stock Forecast page.
Spark’s Take on ONCY Stock
According to Spark, TipRanks’ AI Analyst, ONCY is a Neutral.
The score is primarily constrained by very weak financial performance (no revenue, ongoing losses and cash burn, and negative equity). Technicals are neutral-to-slightly bearish and valuation support is limited due to unprofitability. Positive corporate developments (Fast Track designation, new trial activity, and planned FDA meeting) provide an offset but do not outweigh the current financial risk profile.
To see Spark’s full report on ONCY stock, click here.
More about Oncolytics Biotech
Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent. The company targets gastrointestinal and breast cancers, advancing pelareorep in combination with chemotherapy and checkpoint inhibitors, and holds FDA Fast Track designations in colorectal and pancreatic cancer.
Average Trading Volume: 1,263,636
Technical Sentiment Signal: Sell
Current Market Cap: $119.6M
For a thorough assessment of ONCY stock, go to TipRanks’ Stock Analysis page.